In human epidermis, germinative cell production is determined by three parameters: the cell cycle time, the loss of cycling cells by programmed cell death and the proportion of keratinocytes actively engaged in the cell cycle or growth fraction. The last parameter is still a subject of debate as the identification of a proliferative cell with certainty is impossible. Two indirect methods (grain count dilution of labelled cells and continuous labelling) suggest that non-proliferative cells may exist in the germinative compartment of human epidermis. Results obtained in vitro demonstrate that keratinocytes can be blocked in certain conditions in a state of quiescence similar to a G₀ phase. Increasing evidence suggests that, as in mouse epidermis, the germinative compartment of human epidermis is heterogeneous and is divided into a small proportion of stem cells (10%) with a high proliferative potential, a larger proportion of transit-amplifying cells with a limited proliferative potential (50%) and postmitotic cells committed to undergo terminal differentiation (40%). In this hierarchical arrangement, most of the non-proliferative cells belong to the postmitotic compartment. If this model is correct, the germinative cell population in a quiescent or G0 state is a small proportion of the stem cell compartment and has therefore little influence on the kinetics of normal human epidermis.

Keywords:
Cell proliferation, Growth fraction, Stem cells
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.